Aurinia Pharmaceuticals AUPH Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $41.01M-48.9% | $80.21M+9.6% | $73.19M+38.1% | $53M-20.2% | $66.43M-20.4% | ||
| $49.18M+18.6% | $41.45M+34.9% | $30.73M-23.4% | $40.09M-0.6% | $40.35M+10.4% | ||
| $183.4M+0.1% | $183.18M+3.7% | $176.72M+3.6% | $170.64M+4.7% | $162.99M+4.1% | ||
| $480.24M-2.4% | $491.97M+12.1% | $438.74M+7.3% | $408.97M+0.8% | $405.76M-9.1% | ||
| $1.99M-5.9% | $2.11M-6.8% | $2.27M-6.4% | $2.42M-6.0% | $2.58M-5.7% | ||
| $3.59M-4.5% | $3.76M-3.6% | $3.9M-3.6% | $4.05M-2.7% | $4.16M-4.5% | ||
| $724M-3.7% | $751.59M+42.5% | $527.53M+5.0% | $502.56M-0.5% | $504.85M-8.3% | ||
| $2.66M-19.7% | $3.31M+49.6% | $2.21M-33.2% | $3.31M-21.5% | $4.22M-18.6% | ||
| $5.04M+35.4% | $3.72M-19.2% | $4.6M-16.3% | $5.5M+19.7% | $4.59M-58.2% | ||
| $16.52M0.0% | $16.52M+1.3% | $16.31M+0.9% | $16.17M+11.4% | $14.51M+3.3% | ||
| $86.56M-7.6% | $93.72M+23.0% | $76.22M-2.6% | $78.27M+14.4% | $68.41M-30.0% | ||
| $156.37M-8.2% | $170.26M+5.3% | $161.76M-3.3% | $167.26M+8.1% | $154.66M-10.7% | ||
| $1.09B-3.0% | $1.12B+0.3% | $1.12B-0.5% | $1.12B-3.5% | $1.16B-2.1% | ||
| -$615.01M+5.3% | -$649.37M+24.5% | -$860.16M+3.5% | -$891.71M+2.4% | -$913.23M+2.5% | ||
| $567.63M-2.4% | $581.33M+58.9% | $365.77M+9.1% | $335.3M-4.3% | $350.19M-7.2% | ||
| $724M-3.7% | $751.59M+42.5% | $527.53M+5.0% | $502.56M-0.5% | $504.85M-8.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Aurinia Pharmaceuticals cover its short-term obligations?
- Its current ratio is 5.55 — current assets exceed current liabilities.
- Where does Aurinia Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.